[A case of recurrence of cerebral hemorrhage in a patient with adult moyamoya disease in the recovery period rehabilitation ward].

A 61-year-old woman with a history of repeated cerebral hemorrhage due to moyamoya disease was admitted to our recovery period rehabilitation ward for walking training. She suddenly noticed paresthesia in her left forearm and the palm seven days later. Brain computed tomography on that day and magnetic resonance imaging on the next day after the onset of paresthesia revealed right thalamic hemorrhage. It was suggested that the hematoma localized to a small part of the central portion of the ventroposterior lateral nucleus caused paresthesia limited to the forearm and the palm. In a recovery period rehabilitation ward, we should carefully listen to the complaints of patients who are in advanced age and have a risk like our patient. Then adequate neurological examination should be performed for the pertinent inspection diagnosis, if needed.

Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides.

The tumor cells' acquisition of resistance to multiple drugs due to overexpression of the multidrug resistance protein (MPRP)1 gene is one of major obstacles in cancer chemotherapy. We have attempted to reverse the multidrug resistance (MDR) phenotype by treating etoposide resistant glioma cell lines (T98G-VP and Gli36-VP) with RP1 antisense oligonucleotides. 20-mer phosphorothioate oligodeoxynucleotide (0.3 microM), complementary to the coding region in the MRP cDNA sequence, could significantly inhibit the growth of multidrug resistant cell lines, T98G-VP and Gli36-VP, cultured in etoposide containing medium. No such effect was observed for the parental T98G and Gli36 cell lines. Further investigations by the reverse transcription-polymerase chain reaction and immunoblotting revealed that antisense oligomer could result in a reduction in the level of MRP1 mRNA, probably through hindering MRP1 gene transcription. This study demonstrates that the antisense oligonucleotides can increase the sensitivity of the tumor cells to the anticancer drug by decreasing the expression of the MRP gene. This strategy may be applicable to cure cancer patients with MRP mediated MDR phenotype.